Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation

McKimm-Breschkin, Jennifer L.; Barrett, Susan

doi:10.1016/j.antiviral.2014.12.004

Cited by 15 publications

(16 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…So far, the only antiviral drugs approved by the FDA which successfully inhibit release of progeny virions are NAIs (neuraminidase inhibitors). The two effective drugs present in this class are oseltamivir (OTV) and zanamivir, with the availability of two newer drugs, peramivir and laninamivir, in Japan and South Korea since 2010 (McKimm-Breschkin & Barrett, 2015;Singh & Soliman, 2015). These drugs have been designed based on the crystal structures of group-2 NA (N2, N3, N6, N7 and N9) (von Itzstein, 2007).…”

Section: Introductionmentioning

confidence: 99%

The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern

Schaduangrat

Phanich

Rungrotmongkol

et al. 2016

Journal of General Virology

View full text Add to dashboard Cite

Viral adaptability and survival arise due to the presence of quasispecies populations that are able to escape the immune response or produce drug-resistant variants. However, the presence of H5N1 virus with natural mutations acquired without any drug selection pressure poses a great threat. Cloacal samples collected from the 2004-2005 epidemics in Thailand from Asian open-billed storks revealed one major and several minor quasispecies populations with mutations on the oseltamivir (OTV)-binding site of the neuraminidase gene (NA) without prior exposure to a drug. Therefore, this study investigated the binding between the NA-containing novel mutations and OTV drug using molecular dynamic simulations and plaque inhibition assay. The results revealed that the mutant populations, S236F mutant, S236F/C278Y mutant, A250V/V266A/P271H/G285S mutant and C278Y mutant, had a lower binding affinity with OTV as compared with the WT virus due to rearrangement of amino acid residues and increased flexibility in the 150-loop. This result was further emphasized through the IC 50 values obtained for the major population and WT virus, 104.74 nM and 18.30 nM, respectively. Taken together, these data suggest that H5N1 viruses isolated from wild birds have already acquired OTV-resistant point mutations without any exposure to a drug.

show abstract

Section: Introductionmentioning

confidence: 99%

The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern

Schaduangrat

Phanich

Rungrotmongkol

et al. 2016

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…Mutations at the location affecting the laninamivir dissociation rate can confer a dramatic resistance to laninamivir (46). Some studies have reported that mutations conferring zanamivir resistance also induce resistance to laninamivir with the loss of slow binding and/or faster dissociation (46), also relevant to our results (Table 1) Peramivir contains a guanidino group, as does zanamivir, and a hydrophobic group, as does oseltamivir; consequently, mutations affecting the activities of oseltamivir and zanamivir can also confer resistance to peramivir (47), and is supported by our results.…”

Section: Discussionmentioning

confidence: 99%

<i>In vitro</i> evaluation of the antiviral activity of methylglyoxal against influenza B virus infection

Charyasriwong

Haruyama

Kobayashi

2016

DD&T

View full text Add to dashboard Cite

“…The IC 50 values generated in NI assays also provide information for comparison of inhibitory effects of different NAIs thus aiding in identification of cross-resistant viruses. Variations in IC 50 values determined for the same virus and drug can arise from sources such as use of different enzyme substrates (fluorescent vs chemiluminescent), buffer systems, time of incubation, and other assay conditions (Nguyen et al, 2010;McKimm-Breschkin et al, 2003;McKimm-Breschkin and Barrett, 2014;Tisdale, 2000). The goal of the standardization process was to achieve consistency of IC 50 data across participating laboratories through the application of uniform NI assay testing procedures (same kit and assay protocol) with support from the CDC reference laboratory.…”

Section: Discussionmentioning

confidence: 99%

Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance

et al. 2016

View full text Add to dashboard Cite

Okomo-Adhiambo, M.; Mishin, V.P.; Sleeman, K.; Saguar, E.; Guevara, H.; Reisdorf, E.; Griesser, R.H.; Spackman, K.J.; Mendenhall, M.; Carlos, M.P.; Healey, B.; St. George, K.; Laplante, J.; Aden, T.; Chester, S.; Xu, X.; and Gubareva, L.V., "Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance" (2016 a b s t r a c tBackground: Monitoring influenza virus susceptibility to neuraminidase (NA) inhibitors (NAIs) is vital for detecting drug-resistant variants, and is primarily assessed using NA inhibition (NI) assays, supplemented by NA sequence analysis. However, differences in NI testing methodologies between surveillance laboratories results in variability of 50% inhibitory concentration (IC 50 ) values, which impacts data sharing, reporting and interpretation. In 2011, the Centers for Disease Control and Prevention (CDC), in collaboration with the Association for Public Health Laboratories (APHL) spearheaded efforts to standardize fluorescence-based NI assay testing in the United States (U.S.), with the goal of achieving consistency of IC 50 data. Methods: For the standardization process, three participating state public health laboratories (PHLs), designated as National Surveillance Reference Centers for Influenza (NSRC-Is), assessed the NAI susceptibility of the 2011e12 CDC reference virus panel using stepwise procedures, with support from the CDC reference laboratory. Next, the NSRC-Is assessed the NAI susceptibility of season 2011e12 U.S. influenza surveillance isolates (n ¼ 940), with a large subset (n ¼ 742) tested in parallel by CDC. Subsequently, U.S. influenza surveillance isolates (n ¼ 9629) circulating during the next three influenza seasons (2012e15), were independently tested by the three NSRC-Is (n ¼ 7331) and CDC (n ¼ 2298).Results: The NI assay IC 50 s generated by respective NSRC-Is using viruses and drugs prepared by CDC were similar to those obtained with viruses and drugs prepared in-house, and were uniform between laboratories. IC 50 s for U.S. surveillance isolates tested during four consecutive influenza seasons (2011 e15) were consistent from season to season, within and between laboratories. Conclusion: These results show that the NI assay is robust enough to be standardized, marking the first time IC 50 data have been normalized across multiple laboratories, and used for U.S. national NAI susceptibility surveillance.Published by Elsevier B.V.

show abstract

Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation

Cited by 15 publications

References 20 publications

The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern

The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern

<i>In vitro</i> evaluation of the antiviral activity of methylglyoxal against influenza B virus infection

Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance

Contact Info

Product

Resources

About